Aion Therapeutic Inc (TSE:AION) has released an update.
Aion Therapeutic Inc. has acquired the global licensing rights for I2Pure Corp’s patented molecular iodine, aiming to revolutionize water disinfection through Toppen Health’s advanced filtration systems. The new technology will enable the removal of pathogens, PFAS, and pharmaceuticals, promising cleaner water with the help of I2Pure’s slow-release iodine. The deal includes a cash payment and share payments totaling USD $1.25 million.
For further insights into TSE:AION stock, check out TipRanks’ Stock Analysis page.
